Your science is world-class. Is your IP?
Unbiased IP strategies for biotech, synbio and precision-fermentation founders. Investors check what you own before they check what you've discovered. Biophile builds IP strategies that survive diligence and add to your valuation: independent narratives that bring the science, the IP and the opportunity together.
IAM Strategy 300 Global Leader, several years running · Genetics, IP law and Bioscience Enterprise (MPhil, Cambridge) · Former medtech co-founder · Investor-side diligence experience · Australia, UK & Europe
Fig. 1: the anatomy of an investable biotech.
Your invention is the plasmid. Around it sit the six dimensions investors judge, weighted as in the Biophile IP Readiness Kit. Click any of them.
Plasmid:
your invention
What changes when the IP is right (clients unnamed for confidentiality)
Approximate US dollar equivalents of A$480 million and A$1 billion.
“I'm the patent attorney who doesn't file patents. So my advice is about what your company is worth, not how many filings it has.” – Carel Smit, founder
Three steps from lab to term sheet.
- 1 Score it The free IP Readiness Scorecard. Five minutes, your three priorities. Start →
- 2 Fix it The Biophile IP Readiness Kit (US$497), or IP Ready, which adds a monthly founders' group call and weekly written answers, at US$190 a month billed quarterly. See IP Ready →
- 3 Raise on it The Investor-Ready IP Sprint. Four to six weeks, US$9,500–22,000, fixed after a scoping call. Ask about a sprint →
About Biophile.
Biophile is an independent IP strategy practice for life sciences companies. I founded it to give biotech founders what I wished I'd had as one: advice shaped by what the company is worth, not by how many filings it can generate.
My training covers the three things your company is made of: three degrees in genetics, two in law, and an MPhil in Bioscience Enterprise from the University of Cambridge.
I co-founded Photon Therapy Systems, which took an LED-based wound-healing device to CE marking and into fifteen countries. Later I assessed startups' IP from the investor side for a European life sciences investor.
I have been named in the IAM Strategy 300 Global Leaders, IAM's guide to the world's leading IP strategists, several years running. Companies using my IP strategies have raised more than A$480 million in publicly disclosed financing over the past five years, with value uplifts exceeding A$1 billion. Today I work with startups, spin-outs, investors and research institutes in Europe, the UK and Australia, across synthetic biology, precision fermentation, alternative proteins, biomaterials, biologics, food systems and medtech. I've also written two books for founders: IP Is Everything and Investable Biology.
Find out what an investor would find. Before they do.
Get your free IP Readiness score →
Talk to Carel.
A question about the Kit, a decision you're weighing, or a raise on the horizon. Tell me where you are and I'll come back to you.
Prefer email? contact@biophile.com.au
Please don't include unpublished invention details or trade secrets. We'll go into specifics once we've agreed how to work together.